Literature DB >> 21169263

Do rectal cancer patients with PIK3CA mutations benefit from preoperative radiotherapy with regard to local recurrences?

Youji He, Laura J Van't Veer, Marta Lopez-Yurda, Cornelis J H van de Velde, Corrie A M Marijnen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21169263     DOI： 10.1158/1078-0432.CCR-10-1437

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  4 in total

1.  The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers.

Authors:  Rob Glynne-Jones; Maher Hadaki; Mark Harrison
Journal:  J Gastrointest Oncol       Date:  2013-09

2.  Selecting patients with locally advanced rectal cancer for neoadjuvant treatment strategies.

Authors:  Alice Dewdney; David Cunningham; Ian Chau
Journal:  Oncologist       Date:  2013-07-02

3.  PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases.

Authors:  Etay Ziv; Michael Bergen; Hooman Yarmohammadi; F Ed Boas; E Nadia Petre; Constantinos T Sofocleous; Rona Yaeger; David B Solit; Stephen B Solomon; Joseph P Erinjeri
Journal:  Oncotarget       Date:  2017-04-04

4.  Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery.

Authors:  Olfa Derbel; Qing Wang; Françoise Desseigne; Michel Rivoire; Pierre Meeus; Patrice Peyrat; Mattia Stella; Isabelle Martel-Lafay; Anne-Isabelle Lemaistre; Christelle de La Fouchardière
Journal:  BMC Cancer       Date:  2013-04-23       Impact factor: 4.430
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.